<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019916</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067279</org_study_id>
    <secondary_id>NCI-99-C-0138</secondary_id>
    <secondary_id>NCI-NMOB-9902</secondary_id>
    <secondary_id>NCI-T99-0075</secondary_id>
    <nct_id>NCT00019916</nct_id>
    <nct_alias>NCT00001828</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer</brief_title>
  <official_title>Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Adenocarcinoma of the Breast or Ovary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
      Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. It is not yet&#xD;
      known whether combining vaccine therapy with interleukin-2 is effective in treating breast&#xD;
      and ovarian cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and&#xD;
      interleukin-2 and to see how well they work in treating women with stage IV, recurrent, or&#xD;
      progressive breast or ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether endogenous cellular immunity to the p53 peptide vaccine is present in&#xD;
           patients with stage IV, recurrent, or progressive breast or ovarian cancer and whether&#xD;
           vaccination with these peptides and low-dose interleukin-2 can induce or boost the&#xD;
           cellular immunity in these patients.&#xD;
&#xD;
        -  Determine the type and characteristics of cellular immunity generated by this regimen in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Correlate any immunologic response with any objective tumor response to this regimen in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, pilot study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      All patients undergo apheresis of autologous peripheral blood mononuclear cells, which are&#xD;
      harvested and selected for monocytes on day -6. The monocyte fraction is cultured with&#xD;
      sargramostim (GM-CSF) and interleukin-4 for 7 days and then pulsed with p53 peptide vaccine.&#xD;
&#xD;
        -  Arm I: Patients receive p53 peptide vaccine subcutaneously (SC) on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive p53 peptide vaccine IV over 5 minutes on day 1. Treatment in&#xD;
           both arms repeats every 3 weeks for a total of 4 vaccinations (4 courses). During&#xD;
           courses 3 and 4, patients also receive low-dose interleukin-2 (IL-2) SC daily on days&#xD;
           3-7 and days 10-14. Patients with stable or responding disease may continue to receive&#xD;
           vaccine and IL-2 treatment for up to 2 years.&#xD;
&#xD;
      Patients are followed at 1 month and then every 2-4 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 34 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Cellular immunity as measured by Elipsot assay and 51 Cr-release assay at baseline, and every 3 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by CTC v2.0 at baseline, and every 3 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as measured by CT scan at baseline, and every 3 months</measure>
  </secondary_outcome>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>p53 peptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven adenocarcinoma of the breast or ovary&#xD;
&#xD;
          -  Stage IV, recurrent, or progressive disease with no chemotherapy or radiotherapy&#xD;
             options available that would increase survival&#xD;
&#xD;
          -  Tumor tissue available for determination of p53 protein expression and genetic&#xD;
             mutation&#xD;
&#xD;
               -  p53-positive tumor by immunohistochemical analysis&#xD;
&#xD;
          -  HLA-A2.1 positive&#xD;
&#xD;
          -  No prior CNS metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT or SGPT no greater than 4 times normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No myocardial infarction within past 6 months&#xD;
&#xD;
          -  No prior congestive heart failure&#xD;
&#xD;
          -  No prior ventricular arrhythmias or other arrhythmias requiring therapy&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  Must have positive intradermal delayed hypersensitivity test for 1 of the following:&#xD;
&#xD;
               -  Mumps&#xD;
&#xD;
               -  Trichophyton&#xD;
&#xD;
               -  Tetanus&#xD;
&#xD;
               -  Candida&#xD;
&#xD;
               -  PPD&#xD;
&#xD;
          -  No underlying immune deficiency&#xD;
&#xD;
          -  No prior autoimmune disease including, but not limited to, the following:&#xD;
&#xD;
               -  Autoimmune neutropenia, thrombocytopenia, or hemolytic anemia&#xD;
&#xD;
               -  Systemic lupus erythematosus, Sj√∂gren's syndrome, or scleroderma&#xD;
&#xD;
               -  Myasthenia gravis&#xD;
&#xD;
               -  Goodpasture's syndrome&#xD;
&#xD;
               -  Addison's disease&#xD;
&#xD;
               -  Hashimoto's thyroiditis&#xD;
&#xD;
               -  Active Graves' disease&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other active malignancy within the past 2 years except curatively treated carcinoma&#xD;
             in situ of the cervix or basal cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
          -  At least 1 year since prior bone marrow transplantation&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior anticancer hormonal therapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior systemic steroids and recovered&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Chronic suppressive antibiotics allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir N. Khleif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

